Belamicin

Each film-coated tablet contains:

• Spiramycin EP 3 million IU;
• Excipients q.s.
• Approved casing dyes are used.

Treatment of infections caused by microorganisms sensitive to spiramycin:

• Confirmed pharyngitis caused by group A beta-hemolytic streptococcus as an alternative to treatment with beta-lactam antibiotics, especially if they cannot be used;
• Acute sinusitis: given the microbiological characteristics of the infection, the use of macrolides is indicated when treatment with beta-lactam antibiotics is not possible;
• Superinfection in acute bronchitis, exacerbation of chronic bronchitis;
• Community-acquired pneumonia in individuals without risk factors, without severe clinical symptoms, with the absence of clinical factors indicating pneumococcal etiology of the disease;
• In case of suspected atypical pneumonia, the use of macrolides is advisable regardless of the severity of the disease and medical history;
• Skin infections with a benign course: impetigo, impetiginization, ecthyma, infectious dermo-hypodermatitis (especially erysipelas), erythrasma;
• Oral infections;
• Non-gonococcal genital infections;
• Chemoprevention of relapses of rheumatism in patients with allergies to beta-lactam antibiotics;
• Toxoplasmosis in pregnant women;
• Prevention of meningococcal meningitis in persons for whom the use of rifampicin is contraindicated for the purpose of eradicating the microorganism Neisseria meningitidis in the nasopharynx.

Indicated as prevention:

• patients after treatment and before returning to public life;
• in persons who had contact with the patient within 10 days before his hospitalization. Belamicin is not intended for the treatment of meningococcal meningitis.

Official recommendations regarding the appropriate use of antibacterial agents must be followed.

Adults are prescribed 1 tablet of 3 million IU 2 times a day for 5 days.

Patients with impaired renal function due to low renal excretion of spiramycin do not require dose changes.